BR112023006371A2 - Composição oftalmológica tópica - Google Patents

Composição oftalmológica tópica

Info

Publication number
BR112023006371A2
BR112023006371A2 BR112023006371A BR112023006371A BR112023006371A2 BR 112023006371 A2 BR112023006371 A2 BR 112023006371A2 BR 112023006371 A BR112023006371 A BR 112023006371A BR 112023006371 A BR112023006371 A BR 112023006371A BR 112023006371 A2 BR112023006371 A2 BR 112023006371A2
Authority
BR
Brazil
Prior art keywords
topical
ophthalmological composition
topical ophthalmological
composition
ophthalmic composition
Prior art date
Application number
BR112023006371A
Other languages
English (en)
Portuguese (pt)
Inventor
Ni Jinsong
Yang Rong
Original Assignee
Ads Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ads Therapeutics Llc filed Critical Ads Therapeutics Llc
Publication of BR112023006371A2 publication Critical patent/BR112023006371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112023006371A 2020-10-08 2021-10-08 Composição oftalmológica tópica BR112023006371A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089263P 2020-10-08 2020-10-08
US17/317,551 US11191751B1 (en) 2020-10-08 2021-05-11 Topical ophthalmological atropine free base compositions
PCT/US2021/054221 WO2022076852A1 (en) 2020-10-08 2021-10-08 Topical ophthalmological compositions

Publications (1)

Publication Number Publication Date
BR112023006371A2 true BR112023006371A2 (pt) 2023-05-09

Family

ID=78818588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006371A BR112023006371A2 (pt) 2020-10-08 2021-10-08 Composição oftalmológica tópica

Country Status (11)

Country Link
US (2) US11191751B1 (https=)
EP (2) EP4225284B1 (https=)
JP (1) JP2023544853A (https=)
KR (1) KR20230084190A (https=)
CN (1) CN116390714A (https=)
AU (1) AU2021359003A1 (https=)
BR (1) BR112023006371A2 (https=)
CA (1) CA3193940A1 (https=)
ES (1) ES3063371T3 (https=)
MX (1) MX2023004065A (https=)
WO (1) WO2022076852A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.
KR20240136369A (ko) * 2022-01-21 2024-09-13 에이디에스 테라퓨틱스 엘엘씨 8-메틸-8-아자비사이클로[3.2.1] 옥탄-3-일의 에스테르 3-하이드록시-2-페닐프로파노에이트
JP2025541009A (ja) 2022-12-23 2025-12-17 ノバリック ゲーエムベーハー ヒヨスチアミンを含む半フッ化アルカン組成物
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025264886A1 (en) * 2024-06-19 2025-12-26 Btv Holding, Llc Ophthalmic preparations and methods of use
WO2026011139A1 (en) * 2024-07-05 2026-01-08 Ads Therapeutics Llc Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
CN113679699B (zh) * 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) * 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
WO2019068763A1 (en) * 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
TW201932104A (zh) * 2017-11-03 2019-08-16 澳大利亞商布萊恩荷登視覺協會 用於控制及/或降低近視進展之醫藥組合物
SG11202102820VA (en) * 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) * 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.

Also Published As

Publication number Publication date
CN116390714A (zh) 2023-07-04
US20230355594A1 (en) 2023-11-09
EP4706766A2 (en) 2026-03-11
CA3193940A1 (en) 2022-04-14
EP4225284B1 (en) 2025-11-26
WO2022076852A1 (en) 2022-04-14
AU2021359003A1 (en) 2023-05-04
ES3063371T3 (en) 2026-04-16
US11191751B1 (en) 2021-12-07
EP4225284C0 (en) 2025-11-26
KR20230084190A (ko) 2023-06-12
JP2023544853A (ja) 2023-10-25
EP4225284A1 (en) 2023-08-16
MX2023004065A (es) 2023-05-03
AU2021359003A9 (en) 2024-06-13
EP4225284A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
BR112023006371A2 (pt) Composição oftalmológica tópica
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2023009091A (es) Composiciones oftalmologicas topicas.
Aguayo Bonniard et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)
Lu et al. Novel pharmacologic candidates for treatment of primary open-angle glaucoma
MX2019002861A (es) Composicion farmaceutica.
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
MX2020010078A (es) Composicion farmaceutica que comprenden timolol.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
PE20240922A1 (es) Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos
MX2024011079A (es) Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
CL2024002532A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]